You're signed outSign in or to get full access.
Commodore Capital LP
Commodore Capital LP is a hedge fund and financial investment management firm headquartered in New York, NY. Founded to provide investment solutions to high-net-worth individuals, institutions, and family offices, the firm has approximately 12 employees. Commodore Capital specializes in the healthcare and biopharmaceutical sectors, backing early-stage and innovative companies. The firm serves a global clientele, delivering both traditional and alternative investment strategies with a focus on long-term growth. Commodore Capital is known for a client-centric approach, providing comprehensive wealth management, customized financial planning, and disciplined investment advisory services.
Investment Strategy
Commodore Capital LP employs a disciplined investment approach focused on identifying long-term growth opportunities in the healthcare and biopharmaceutical sectors. The firm conducts thorough research to discover high-potential early-stage companies, with an emphasis on scientific breakthroughs, genetic medicines, and cellular therapies. By blending both traditional and alternative investments, Commodore offers a diversified portfolio that aims to mitigate risk and maximize returns. Commodore capitalizes on the current wave of innovation in biopharmaceuticals, partnering closely with companies aiming to deliver transformative therapies to patients worldwide.
Latest 13F Filing Activity
Commodore Capital LP filed their most recent 13F report on Jun 30, 2025 disclosing 33 equity positions with a total 13F market value of $1B. The fund increased holdings in Protagonist Therapeutics Inc., Cidara Therapeutics Inc., Relay Therapeutics Inc. among other positions. Commodore Capital LP reduced exposure to Vaxcyte Inc., Vera Therapeutics Inc., Cogent Biosciences Inc. among others.
Top Holdings
Equity Positions (33)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
M MRUS | MERUS N V | 13.09% | $185.4M | 3,525,000 | $30.24 | $52.60 | -$2.8M |
N NUVL | NUVALENT INC | 7.41% | $104.9M | 1,375,000 | $62.88 | $76.30 | -$26.6M |
X XENE | XENON PHARMACEUTICALS INC | 6.68% | $94.7M | 3,025,000 | $31.46 | $31.30 | +$16.7M |
E ELVN | ENLIVEN THERAPEUTICS INC | 6.64% | $94.1M | 4,692,809 | $19.93 | $20.06 | +$2.1M |
A AGIO | AGIOS PHARMACEUTICALS INC | 5.46% | $77.3M | 2,325,000 | $29.54 | $33.26 | +$13.3M |
Industry Allocation
Investment Team (2)
| Name | Role | Location | |
|---|---|---|---|
 | Head Trader | Hoboken, NJ , United States | |
J John Brock | Partner | New York, NY , United States |
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more